Medpace (NASDAQ:MEDP) CEO August Troendle Sells 14,747 Shares

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 14,747 shares of the business’s stock in a transaction on Friday, November 14th. The stock was sold at an average price of $595.26, for a total transaction of $8,778,299.22. Following the completion of the transaction, the chief executive officer directly owned 899,415 shares in the company, valued at $535,385,772.90. This trade represents a 1.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Medpace Stock Performance

Shares of NASDAQ:MEDP opened at $590.18 on Wednesday. The firm has a fifty day moving average price of $543.35 and a 200 day moving average price of $428.47. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $625.00. The firm has a market cap of $16.62 billion, a price-to-earnings ratio of 41.27, a P/E/G ratio of 2.67 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. The company had revenue of $659.90 million for the quarter, compared to the consensus estimate of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. Medpace’s revenue for the quarter was up 23.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Rothschild & Co Redburn lowered Medpace from a “buy” rating to a “neutral” rating and increased their price target for the company from $342.00 to $474.00 in a research note on Wednesday, September 3rd. TD Cowen lifted their price objective on Medpace from $356.00 to $462.00 and gave the stock a “sell” rating in a research note on Friday, October 24th. Deutsche Bank Aktiengesellschaft increased their target price on Medpace from $270.00 to $430.00 and gave the company a “hold” rating in a research report on Wednesday, July 23rd. Rothschild Redb cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 3rd. Finally, Truist Financial set a $555.00 price target on shares of Medpace in a research note on Monday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have assigned a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $487.18.

Institutional Trading of Medpace

A number of institutional investors have recently bought and sold shares of MEDP. Quent Capital LLC purchased a new stake in shares of Medpace in the third quarter valued at $25,000. Optiver Holding B.V. purchased a new position in shares of Medpace during the 3rd quarter worth about $27,000. Quarry LP bought a new position in Medpace during the 3rd quarter valued at about $35,000. Root Financial Partners LLC purchased a new stake in Medpace in the 3rd quarter worth about $38,000. Finally, Geneos Wealth Management Inc. raised its position in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the period. 77.98% of the stock is currently owned by institutional investors.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.